TAXUS Liberté Attenuates the Risk of Restenosis in Patients With Medically Treated Diabetes Mellitus
Results From the TAXUS ATLAS Program
Ehtisham Mahmud, John A. Ormiston, Mark A. Turco, Jeffrey J. Popma, Neil J. Weissman, Charles D. O'Shaughnessy, Tift Mann, Jack J. Hall, Thomas F. McGarry, Louis A. Cannon, Mark W.I. Webster, Lazar Mandinov and Donald S. Baim
Cumulative Frequency Distribution of 9-Month In-Stent and In-Segment Late Loss by Quantitative Coronary Angiography
Subjects with and without diabetes treated with the TAXUS Liberté Stent in the TAXUS ATLAS studies. (A) In-stent; and (B) in-segment. Intent-to-treat, angiographic subset (n = 1,201; diabetic: 334; nondiabetic: 867).